Sarah Bennett
Bacterial vaccines are an important tool in the fight against bacterial infections, which were the second leading cause of death in the UK in 2019, with around 87,500 fatalities. These vaccines contain killed or attenuated bacteria that activate the immune system to build antibodies and prevent future bacterial infections. While vaccines for some bacteria, such as tuberculosis, cholera, and typhoid, have been developed and perfected, researchers are still working to create effective vaccines for other bacteria, including Pseudomonas aeruginosa, Staphylococcus aureus, and Neisseria gonorrhoeae. The development of bacterial vaccines faces challenges due to the complex nature of bacterial infections and the need to induce specific immune responses at mucosal sites. However, advancements in biotechnology and genome sequencing are aiding the creation of a new generation of vaccines, offering hope in the battle against drug-resistant bacteria.
| Characteristics | Values |
|---|---|
| Bacterial vaccines contain | Killed or attenuated bacteria |
| Bacterial vaccines activate | The immune system |
| Bacterial vaccines prevent | Bacterial infection |
| Example of a bacterial vaccine | Tuberculosis vaccine |
| Bacterial infections | Second leading cause of death in the UK in 2019 |
| Bacterial infections caused | 87,500 fatalities in the UK in 2019 |
| Bacterial infections are caused by | Pseudomonas aeruginosa, Staphylococcus aureus, and Neisseria gonorrhoeae |
| Bacterial vaccines are | More efficient than viral vaccines |
| Bacterial vaccines | Do not change over time |
| Bacterial vaccines | Do not need to be altered |
| Bacterial vaccines | Do not need to be updated |
| Bacterial vaccines are made | Recombinantly through DNA |
| Live bacterial vectors used for antigen delivery include | Mucosal pathogens that have been attenuated |
| Mucosal pathogens include | Listeria monocytogenes, Salmonella, Vibrio cholera, Shigella, Mycobacteria bovis, Yersinia enterocolitica, and Bacillus anthracis |
Explore related products
What You'll Learn
- Bacterial infections were the second leading cause of death in the UK in 2019
- Bacterial vaccines contain killed or attenuated bacteria
- The development of vaccines for N. gonorrhoeae, S. aureus and P. aeruginosa is challenging
- Live bacterial vectors used for antigen delivery
- Bacterial vaccines are more efficient than viral vaccines
Bacterial infections were the second leading cause of death in the UK in 2019
Bacterial infections were the second leading cause of death globally in 2019, including in the UK. They were second only to ischaemic heart disease. Of the estimated 13.7 million infection-related deaths that occurred in 2019, 7.7 million were associated with 33 common bacterial pathogens. These deaths accounted for 13.6% of all global deaths and more than half of all sepsis-related deaths.
The Global Research on Antimicrobial Resistance (GRAM) Project, hosted by the Centre for Tropical Medicine and Global Health at the Nuffield Department of Medicine, found that five bacteria alone were connected to half of the 7.7 million deaths. The deadliest bacterial pathogens and types of infection varied by location and age. The pathogen associated with the most deaths globally was S. aureus, with 1.1 million deaths. Four other pathogens were each associated with more than 500,000 deaths: E. coli (950,000 deaths), S. pneumoniae (829,000), K. pneumoniae (790,000), and Pseudomonas aeruginosa (559,000).
The GRAM study estimated that bacterial AMR caused more than 1.2 million deaths in 2019. The study called for further interventions, including infection prevention and control, stronger health systems with greater diagnostic laboratory capacity, implementing control measures, and optimising antibiotic use.
While there are vaccines available to prevent certain bacterial infections, such as the tuberculosis vaccine, there are many bacterial infections for which vaccines have not yet been developed. These include infections caused by Pseudomonas aeruginosa, Staphylococcus aureus, and Neisseria gonorrhoeae. Researchers are working to develop vaccines for these and other bacterial pathogens, but there are challenges to overcome, such as the complex immune responses to certain bacteria and the development of antibiotic resistance.
Super Bowl Fans: Are They All Vaccinated?
You may want to see also
Explore related products
Bacterial vaccines contain killed or attenuated bacteria
Bacterial vaccines are designed to boost the immune system, reduce the risk of infection, and lessen the severity of infections. They contain killed or attenuated bacteria that activate the immune system. The process of vaccination involves imitating an infection to engage the body's natural defences. The active ingredient in all vaccines is an antigen, which causes the immune system to begin producing antibodies.
Bacterial vaccines contain bacteria that have been attenuated, or weakened, to the point where they can no longer cause disease. These attenuated bacteria are still alive, but they are unable to replicate within cells. This means that they can invade host cells and induce an immune response, but they cannot cause a full-blown infection. Live-attenuated vaccines can provide enduring protection with only two doses, as they contain living bacteria or viruses.
One example of a bacterial vaccine is the oral cholera vaccine (Vaxchora). In this vaccine, the gene encoding for the toxigenic subunit of cholera toxin has been deleted, resulting in a non-toxic, attenuated bacterial strain. Another example is the tuberculosis vaccine, which contains killed or attenuated Mycobacterium tuberculosis bacteria.
In addition to live-attenuated vaccines, there are also inactivated or killed bacterial vaccines. These vaccines contain bacteria that have been treated with chemicals or heat to render them non-infectious while preserving their ability to trigger an immune response. An example of an inactivated bacterial vaccine is the tetanus vaccine, which contains tetanus toxoid.
Bacterial vaccines are an important tool for preventing and controlling bacterial infections, and they have been successfully used to protect against a variety of diseases, including tuberculosis, cholera, and tetanus.
MMR Vaccine: When Did It Begin?
You may want to see also
Explore related products
The development of vaccines for N. gonorrhoeae, S. aureus and P. aeruginosa is challenging
Bacterial vaccines are designed to generate a protective immune response against microbial invaders. They contain killed or attenuated bacteria that activate the immune system, allowing antibodies to be built against that particular bacteria.
Despite years of effort, researchers have been unable to develop vaccines for certain bacterial pathogens, including Pseudomonas aeruginosa, Staphylococcus aureus, and Neisseria gonorrhoeae. These bacteria are responsible for a range of infections and diseases, such as sepsis, pneumonia, and gonorrhea, a sexually transmitted infection with a high global incidence.
The development of vaccines for these bacteria is challenging due to several factors. Firstly, N. gonorrhoeae does not induce protective immunity following natural infection, and the antibody response is complicated. There is also limited knowledge about T cell immunity to N. gonorrhoeae, which may be important for developing effective vaccines.
In the case of S. aureus, pre-exposure shapes immune responses and can influence the effectiveness of vaccine-induced protection. Studies have shown that in mice naïve to S. aureus, a vaccine targeting a bacterial surface protein elicited a protective antibody response, but pre-exposure to the bacteria resulted in the production of non-protective antibodies.
Additionally, P. aeruginosa, S. aureus, and N. gonorrhoeae possess surface structures and secreted factors that facilitate colonization and infection. For example, the membrane of P. aeruginosa contains lipopolysaccharides, lipoproteins, and dozens of porin proteins involved in molecular transport, antibiotic resistance, and surface binding. These complex structures and factors make it challenging to develop effective vaccines.
While the development of vaccines for these bacteria is challenging, advancements in research provide hope. For instance, humanized transgenic mice have enabled researchers to study interactions between microbial vaccine targets and human receptors for N. gonorrhoeae. Additionally, recent data suggest that vaccines for gonorrhea may be biologically feasible, and vaccine candidates are currently in preclinical development.
Chicken Egg Vaccines: How Do They Work?
You may want to see also
Explore related products
Live bacterial vectors used for antigen delivery
Bacterial vaccines contain killed or attenuated bacteria that activate the immune system, creating antibodies to prevent bacterial infection. For example, the Tuberculosis vaccine.
Live bacterial vectors are used for antigen delivery, and they have been extensively studied over the last 30 years. They possess several advantages, including:
- Inexpensive and flexible manufacturing processes.
- Multiple vaccination routes, including oral, intranasal, ocular, rectal, vaginal, and pulmonary inhalation.
- Well-characterized mutations for virulence attenuation.
- Availability of antibiotic-susceptible vaccine vectors, allowing treatment with antibiotics if adverse reactions occur.
- Tropism towards lymphoid antigen-presenting cells in the intestinal mucosal tract, making them ideal for developing mucosal vaccines.
Live bacterial vectors are constructed from pathogenic microorganisms such as Salmonella, Listeria, and Mycobacterium. However, these pathogenic strains retain some virulence, making them unsuitable for vulnerable individuals such as infants, the elderly, or immunocompromised patients. To address this, non-pathogenic microorganisms like lactic acid bacteria have been explored as antigen delivery vehicles.
Live bacterial vectors have been investigated for their potential in preventing infectious diseases and treating cancers. They can deliver heterologous antigens or genes encoding anti-cancer molecules. For example, Yang et al. constructed a DNA vaccine against T. spiralis, inducing antigen-specific mucosal IgA and protecting against T. spiralis larval challenge.
While significant progress has been made, challenges remain in developing vaccines for certain pathogens, such as Pseudomonas aeruginosa, Staphylococcus aureus, and Neisseria gonorrhoeae.
Polio Vaccine: Synonyms and Their Significance
You may want to see also
Explore related products
Bacterial vaccines are more efficient than viral vaccines
Bacterial and viral vaccines are two distinct types of inoculations. Bacterial vaccines are for diseases caused by bacteria, whereas viruses require a host. Bacteria can live independently and do not change their genetic structure quickly or easily. This means that vaccines against bacteria are much more efficient than those against viruses.
Bacterial vaccines can be recombinant, which are novel strategies that use live attenuated bacteria as vectors of recombinant genes. These vaccines are more efficient, stronger, and better characterized, as well as offering a wider defence against various serotypes of a bacterium. Recombinant vaccines also have the advantage of being less reactive, which is important when using subunit vaccines that result in poor immunity when administered alone.
Viral vaccines, on the other hand, have to be frequently updated to combat the rapidly mutating genetic material of viruses. This means that individuals must receive vaccinations more often and with updated vaccines. Viral vaccines are typically administered in at least three doses to achieve protection, whereas bacterial vaccines can provide enduring protection with only two doses.
Furthermore, bacterial vaccines can induce antibody production and protect against lethal pathogens. For example, immunization with outer membrane vesicles (OMVs) has been shown to protect animals from lethal pathogens such as V. cholerae and B. pertussis. Bacterial vaccines can also prevent diseases like meningitis and bacteremia/septicemia by inducing antibody responses to specific serotypes.
In summary, bacterial vaccines are more efficient than viral vaccines due to the independent nature of bacteria and their slower rate of genetic mutation. Recombinant bacterial vaccines offer improved efficiency, stronger protection, and wider defence against various serotypes. Viral vaccines, meanwhile, face the challenge of constantly evolving viruses and require more frequent vaccinations with updated formulas.
AI-Powered mRNA Vaccines: Immune Response Stoppers
You may want to see also
Frequently asked questions
Bacterial vaccines contain killed or attenuated bacteria that activate the immune system. Antibodies are built against that particular bacteria, preventing bacterial infection later.
Bacteria can live independently of a host, unlike viruses, and do not change their genetic structure quickly or easily. As a result, vaccines against bacteria are much more efficient and do not need to be altered or updated frequently.
Yes, bacterial infections are still killing millions of people worldwide. The emergence of multidrug resistance in many clinically relevant bacterial pathogens has renewed interest in developing efficient, safe, and affordable vaccines. In some cases, the spectrum of effective antibiotics is limited, and alternatives are rare.
Yes, one example of a bacterial vaccine is the Tuberculosis (TB) vaccine. Other examples include the new generation live oral cholera vaccine (Vaxchora) and the Bacillus Calmette-Guerin (BCG) vaccine, which is given as a booster to prevent persistent seroconversion.
